Erlonix150 mg

Erlonix 150 mg is an oral targeted cancer therapy (a tyrosine kinase inhibitor) used, as part of an oncologist-directed treatment plan, for:

Non-Small Cell Lung Cancer (NSCLC)

• Maintenance treatment of locally advanced or metastatic NSCLC in patients whose disease has not progressed after first-line chemotherapy
• Second- or third-line treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen
• Some regulatory approvals and clinical guidelines specifically favour use in tumours with an activating epidermal growth factor receptor (EGFR) mutation, where response rates are substantially higher

Pancreatic Cancer

• In combination with gemcitabine, for the first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer

Erlonix 150 mg is a prescription-only oncology medicine used exclusively under the supervision of a cancer specialist, as part of an individualized treatment plan that may include prior EGFR mutation testing to guide the decision to treat.

Contains Erlonix 150 mg (as Erlonix 150 mg hydrochloride) as the active ingredient, available as oral film-coated tablets, commonly in 25 mg, 100 mg, and 150 mg strengths.

Erlonix 150 mg is an oral, targeted anticancer medicine that blocks a specific growth signal used by certain lung and pancreatic cancer cells to grow and divide. Unlike traditional chemotherapy, which affects rapidly dividing cells throughout the body, Erlonix 150 mg specifically targets the epidermal growth factor receptor (EGFR) pathway, which is often overactive or mutated in these cancers. It is taken once daily on an empty stomach and is used either alone for certain lung cancers or combined with chemotherapy for pancreatic cancer.

Therapeutic Class: Targeted Anticancer Agent (Antineoplastic)

Erlonix 150 mg is absorbed variably after oral administration, with peak plasma concentrations reached approximately 4 hours after an oral dose; bioavailability is substantially higher when taken with food (up to nearly 100%) compared to a fasting state (around 60%), which is why Erlonix 150 mg is specifically directed to be taken on an empty stomach to keep absorption predictable and avoid unpredictable increases in exposure. It is extensively metabolized in the liver primarily by CYP3A4 (and to a lesser extent CYP1A2), with an elimination half-life of approximately 36 hours, supporting once-daily dosing. Cigarette smoking significantly induces CYP1A2 and reduces Erlonix 150 mg blood levels, which is why current smokers may require a higher starting dose than non-smokers.

• Take at least 1 hour before or 2 hours after eating any food, since food significantly increases absorption
• Swallow the tablet whole with a glass of water
• Take at approximately the same time each day for consistent blood levels
• If a dose is missed, do not double up take the next scheduled dose as usual and inform your oncology team
• Report smoking status honestly to your oncology team, since it directly affects drug levels and safe dosing

Erlonix 150 mg is primarily metabolized by CYP3A4, making it sensitive to many drug interactions; the following require careful assessment by the oncology team:

• Strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, ritonavir): can significantly raise Erlonix 150 mg blood levels and increase toxicity risk; concurrent use should generally be avoided, or the Erlonix 150 mg dose reduced with close monitoring.
• Strong CYP3A4 inducers (such as rifampicin, phenytoin, carbamazepine, and St. John's Wort): can substantially lower Erlonix 150 mg blood levels, potentially reducing its anticancer effect; alternatives should be considered where possible, or a higher Erlonix 150 mg dose used with close monitoring.
• Cigarette smoking: induces CYP1A2 and reduces Erlonix 150 mg exposure by up to two-thirds; this is one of the most clinically important influences on Erlonix 150 mg dosing and effectiveness.
• Proton pump inhibitors, H2-receptor antagonists, and antacids: Erlonix 150 mg solubility, and therefore absorption, is reduced at higher gastric pH; these acid-reducing medicines can lower Erlonix 150 mg blood levels and should be avoided or carefully timed if unavoidable, under oncologist guidance.
• Warfarin and other anticoagulants: Erlonix 150 mg has been associated with increased INR and bleeding events in some patients on warfarin; more frequent INR monitoring is recommended.
• Statins metabolized by CYP3A4 and other CYP3A4-metabolized medicines: Erlonix 150 mg may alter their blood levels; monitoring or dose adjustment may be needed.

Very common side effects

• Rash (acneiform, affecting the face and upper body) occurs in the majority of patients and may correlate with treatment response
• Diarrhoea
• Fatigue
• Loss of appetite, nausea
• Dry skin, itching

Serious side effects (require prompt medical attention)

• Interstitial lung disease (ILD): new or worsening unexplained shortness of breath, cough, and fever require immediate evaluation, as ILD can be fatal; Erlonix 150 mg is generally interrupted or discontinued if this is suspected.
• Severe hepatotoxicity, including liver failure: yellowing of the skin or eyes, dark urine, and severe abdominal pain warrant urgent liver function testing.
• Gastrointestinal perforation: severe, unexplained abdominal pain requires urgent evaluation, particularly in patients on concomitant anti-angiogenic therapy, corticosteroids, NSAIDs, or with a history of peptic ulcer disease.
• Severe diarrhoea leading to dehydration and kidney injury should be managed promptly with antidiarrheal treatment and, if severe, dose interruption.
• Ocular disorders: corneal perforation or ulceration, abnormal eyelash growth, and severe eye irritation have been reported.
• Severe bullous, blistering, and exfoliating skin conditions some fatal cases have been reported.
• Microangiopathic haemolytic anaemia with thrombocytopenia a rare but serious blood disorder reported in combination with gemcitabine.

Pregnancy

Erlonix 150 mg can cause fetal harm based on its mechanism of action and animal reproduction data. It should not be used during pregnancy; effective contraception is recommended for patients of reproductive potential during treatment and for a defined period afterward, as advised by the treating oncologist.

Breastfeeding

It is not known whether Erlonix 150 mg passes into human milk; breastfeeding is generally not recommended during treatment and for a period afterward, given the potential for serious adverse effects in a nursing infant.

• Interstitial lung disease: a rare but potentially fatal complication; promptly evaluate any new or worsening pulmonary symptoms and interrupt Erlonix 150 mg pending diagnosis.
• Hepatotoxicity: monitor liver function periodically, especially in patients with pre-existing liver disease; dose reduction or interruption is required for significant liver enzyme elevation.
• Renal failure: can occur, particularly in the setting of severe dehydration from diarrhoea, vomiting, or reduced fluid intake; maintain adequate hydration and monitor renal function, especially early in treatment or with combination chemotherapy.
• Smoking status: significantly affects Erlonix 150 mg blood levels; patients should be counselled on smoking cessation, and dosing reassessed if smoking status changes during treatment.
• Gastrointestinal perforation: increased risk with concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane chemotherapy, or a history of peptic ulcer or diverticular disease.
• Skin and eye toxicity: monitor for bullous or exfoliative skin conditions and ocular symptoms, discontinuing promptly if severe reactions occur.
• Acetaminophen (paracetamol) use should be limited during Erlonix 150 mg treatment (some guidelines suggest no more than 1,300 mg/day) given case reports of severe hepatotoxicity with combined high-dose acetaminophen and alcohol use in patients on tyrosine kinase inhibitors of this class; discuss any regular acetaminophen use with the oncology team.

Limited clinical experience with Erlonix 150 mg overdose exists; single doses up to 1,000 mg in healthy volunteers and 1,600 mg in cancer patients have been studied, with adverse effects such as diarrhoea and skin rash observed, generally reversible with dose interruption. Suspected significant overdose should be reported to the treating oncology team immediately; management is supportive, with attention to the known toxicities of the drug (gastrointestinal, hepatic, dermatologic).

Store at controlled room temperature (generally 15-30°C), protected from moisture and light, in the original container. Keep out of reach of children, given the potency of oncology medicines.

• Smokers: Require different dosing considerations, since active smoking reduces Erlonix 150 mg blood levels through CYP1A2 induction; the treating oncologist may consider a higher starting dose, with close monitoring, particularly if the patient later quits smoking.
• Hepatic impairment: Use with caution and close monitoring in patients with liver disease, given the risk of hepatotoxicity; specific dose adjustment should be determined by the treating oncologist.
• Renal impairment: Limited specific data are available; use with caution and monitor renal function, particularly if gastrointestinal toxicity causes dehydration.
• Elderly: Used with the same dosing approach as younger adults, with attention to overall tolerability and organ function.

Treatment continues for as long as the cancer responds and the patient tolerates therapy, or until disease progression or unacceptable toxicity occurs, as determined by the treating oncologist through periodic reassessment, including imaging and clinical evaluation.

Drug Class: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

Erlonix 150 mg works by blocking the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR), a protein on the surface of some cancer cells that, when activated, sends signals driving the cell to grow, divide, and survive. By inhibiting this signalling pathway, Erlonix 150 mg slows or stops the growth of cancer cells that depend on EGFR signalling, particularly effective in tumours with activating EGFR mutations.

Erlonix 150 mg is used in adult oncology practice for the cancers listed under indications; safety and effectiveness have not been established in pediatric patients, and it is not recommended for use in children outside of a specialist clinical trial setting.